CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023
31 Ottobre 2023 - 1:00PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced that
it will report third quarter financial results on Tuesday,
November 7, 2023, after the close of U.S. markets. Following the
announcement, the Company will host a conference call and webcast
at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the
conference call from the Events and Presentations page of CytomX’s
website at https://ir.cytomx.com/events-and-presentations.
Participants may register for the conference call here and are
advised to do so at least 10 minutes prior to joining the call. An
archived replay of the webcast will be available on the Company’s
website.
About CytomX Therapeutics,
Inc.CytomX is a clinical-stage, oncology-focused
biopharmaceutical company focused on developing novel conditionally
activated biologics localized to the tumor microenvironment. By
pioneering a novel class of conditionally activated biologics,
powered by its Probody® technology platform, CytomX’s goal is to
transcend the limits of current cancer treatments. CytomX’s robust
and differentiated pipeline comprises therapeutic candidates across
multiple treatment modalities including antibody-drug conjugates
(“ADCs”), T-cell engaging bispecific antibodies, and immune
modulators such as cytokines and checkpoint inhibitors. CX-2029 is
an investigational conditionally activated ADC directed toward
CD71. CytomX’s clinical pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutic BMS-986288, partnered with
Bristol Myers Squibb, and CX-904, a conditionally activated
T-cell-engaging bispecific antibody targeting the epidermal growth
factor receptor (EGFR) on tumor cells and the CD3 receptor on T
cells, partnered with Amgen. In addition, CytomX has a diverse
preclinical portfolio of wholly-owned assets including CX-801, an
interferon alpha-2b Probody cytokine that has broad potential
applicability in traditionally immuno-oncology sensitive as well as
insensitive (cold) tumors and CX-20511, a conditionally activated
ADC directed toward EpCAM, with potential applicability across
multiple EpCAM-expressing epithelial cancers. CytomX has also
established strategic collaborations with multiple leaders in
oncology, including Amgen, Astellas, Bristol Myers Squibb,
Regeneron and Moderna. For more information about CytomX and how it
is working to make conditionally activated treatments the new
standard-of-care in the fight against cancer, visit
https://cytomx.com/ and follow us on LinkedIn and Twitter.Probody
is a U.S. registered trademark of CytomX Therapeutics, Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accounting cogden@cytomx.comDirect: (317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
_______________1 Licensed from Immunogen
Grafico Azioni CytomX Therapeutics (NASDAQ:CTMX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni CytomX Therapeutics (NASDAQ:CTMX)
Storico
Da Set 2023 a Set 2024